Predictive Oncology Profit Margin

The latest profit margin for POAI is -7006.14% as of June 2026. That compares with -202.72% in the prior-year period — down 3356.1% year over year. That is below the Healthcare sector average of 13.39%. Investors often review this figure alongside Predictive Oncology's historical trend and sector peers before judging valuation or financial health.

Over the past year, POAI's profit margin moved from -202.72% to -7006.14% — a 3356.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Predictive Oncology's valuation or profitability profile.

Against Healthcare companies, POAI currently prints -7006.14% for profit margin, while the sector average sits near 13.39%. That is roughly 52439.3% below the sector mean. Large gaps often invite a closer look at Predictive Oncology's growth, margins, and balance sheet.

Profit Margin shows how effectively Predictive Oncology converts resources into returns. At -7006.14%, POAI may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -202.72% in the prior-year period — down 3356.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting POAI's profit margin (-7006.14%), review year-over-year change from -202.72%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.